73 related articles for article (PubMed ID: 21715128)
1. Correlation between TBARS levels and glycolytic enzymes: the importance to the initial evaluation of clinical outcome of colorectal cancer patients.
Farias IL; Farias JG; Rossato L; Araújo MC; Chiesa J; Morsh V; Schetinger MR
Biomed Pharmacother; 2011 Sep; 65(6):395-400. PubMed ID: 21715128
[TBL] [Abstract][Full Text] [Related]
2. Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives.
Adamo V; Franchina T; Minciullo PL; Pace E; Colonese F; Ricciardi GR; Saitta S; Ferraro M; Spatari G; Gangemi S
J Cell Physiol; 2011 Nov; 226(11):3032-4. PubMed ID: 21302302
[TBL] [Abstract][Full Text] [Related]
3. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
[TBL] [Abstract][Full Text] [Related]
4. D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer.
Inanc M; Er O; Karaca H; Berk V; Ozkan M; Dikilitas M; Elmali F
J BUON; 2013; 18(2):391-7. PubMed ID: 23818351
[TBL] [Abstract][Full Text] [Related]
5. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
7. Type IV collagen as a tumour marker for colorectal liver metastases.
Nyström H; Naredi P; Hafström L; Sund M
Eur J Surg Oncol; 2011 Jul; 37(7):611-7. PubMed ID: 21620632
[TBL] [Abstract][Full Text] [Related]
8. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
Huang MY; Huang ML; Chen MJ; Lu CY; Chen CF; Tsai PC; Chuang SC; Hou MF; Lin SR; Wang JY
Pharmacogenet Genomics; 2011 Jan; 21(1):18-25. PubMed ID: 21057378
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
11. High plasma TIMP-1 and serum CEA levels during combination chemotherapy for metastatic colorectal cancer are significantly associated with poor outcome.
Aldulaymi B; Byström P; Berglund A; Christensen IJ; Brünner N; Nielsen HJ; Glimelius B
Oncology; 2010; 79(1-2):144-9. PubMed ID: 21150229
[TBL] [Abstract][Full Text] [Related]
12. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
[TBL] [Abstract][Full Text] [Related]
13. Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy.
Fountzilas G; Gossios K; Zisiadis A; Svarna E; Skarlos D; Pavlidis N
Med Pediatr Oncol; 1996 May; 26(5):305-17. PubMed ID: 8614363
[TBL] [Abstract][Full Text] [Related]
14. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
15. [A successfully resected case of colorectal cancer with multiple liver metastases treated with FOLFIRI after failure of mFOLFOX6].
Fukuda H; Tazawa K; Sawada S; Nagata T; Uotani H; Hirokawa S; Yamagishi F; Tsukada K
Gan To Kagaku Ryoho; 2008 Mar; 35(3):507-9. PubMed ID: 18347406
[TBL] [Abstract][Full Text] [Related]
16. VEGF -460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma.
Chen MH; Tzeng CH; Chen PM; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Pharmacogenomics J; 2011 Jun; 11(3):227-36. PubMed ID: 20531372
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant chemotherapy with FOLFOX4 regimen after curative resection of liver metastases from colorectal cancer].
Ohnishi T; Kanoh T; Tono T; Danno K; Watanabe A; Nakamura H; Tsukao Y; Inatome J; Kim T; Kagara N; Taniguchi H; Kimura Y; Nakano Y; Monden T; Imaoka S
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2554-6. PubMed ID: 21224637
[TBL] [Abstract][Full Text] [Related]
18. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
Kandutsch S; Klinger M; Hacker S; Wrba F; Gruenberger B; Gruenberger T
Eur J Surg Oncol; 2008 Nov; 34(11):1231-6. PubMed ID: 18272318
[TBL] [Abstract][Full Text] [Related]
19. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
Innominato PF; Giacchetti S; Moreau T; Smaaland R; Focan C; Bjarnason GA; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Lévi F;
Chronobiol Int; 2011 Aug; 28(7):586-600. PubMed ID: 21859417
[TBL] [Abstract][Full Text] [Related]
20. [Four cases of locally advanced colorectal cancer resected successfully after preoperative chemotherapy].
Yoneda A; Okada K; Matsuo M; Kajiyama M; Kishikawa H
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1699-703. PubMed ID: 21996971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
